CN103347537A - 抗叶酸受体α抗体糖型 - Google Patents
抗叶酸受体α抗体糖型 Download PDFInfo
- Publication number
- CN103347537A CN103347537A CN2011800503838A CN201180050383A CN103347537A CN 103347537 A CN103347537 A CN 103347537A CN 2011800503838 A CN2011800503838 A CN 2011800503838A CN 201180050383 A CN201180050383 A CN 201180050383A CN 103347537 A CN103347537 A CN 103347537A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- fra
- acid sequence
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39481210P | 2010-10-20 | 2010-10-20 | |
| US61/394,812 | 2010-10-20 | ||
| PCT/US2011/056966 WO2012054654A2 (en) | 2010-10-20 | 2011-10-19 | Anti-folate receptor alpha antibody glycoforms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103347537A true CN103347537A (zh) | 2013-10-09 |
Family
ID=45975873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800503838A Pending CN103347537A (zh) | 2010-10-20 | 2011-10-19 | 抗叶酸受体α抗体糖型 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120164137A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2629798A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014505012A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140032944A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103347537A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2011317088B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013009275A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2815080A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL225579A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013004202A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2013122843A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012054654A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118344485A (zh) * | 2024-06-18 | 2024-07-16 | 南京欧凯生物科技有限公司 | 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2172487A1 (en) * | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| JP6122948B2 (ja) | 2012-05-15 | 2017-04-26 | モルフォテック, インコーポレイテッド | 胃癌の治療のための方法 |
| SG11201500938XA (en) * | 2012-08-31 | 2015-04-29 | Immunogen Inc | Diagnostic assays and kits for detection of folate receptor 1 |
| CN104884617B (zh) | 2012-12-07 | 2019-02-19 | 协和发酵麒麟株式会社 | 抗folr1抗体 |
| US8956830B2 (en) | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| TWI771890B (zh) | 2013-03-14 | 2022-07-21 | 美商安美基公司 | 用於增加重組蛋白質之甘露糖含量之方法 |
| US9677105B2 (en) | 2013-03-14 | 2017-06-13 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US20140271622A1 (en) * | 2013-03-14 | 2014-09-18 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| NZ717140A (en) | 2013-08-30 | 2022-05-27 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
| EP2871190A1 (en) * | 2013-11-11 | 2015-05-13 | ATLAB Pharma | Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity |
| ES2808853T3 (es) | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
| RS61010B1 (sr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| SG11201704056XA (en) | 2014-11-20 | 2017-06-29 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| CA2969225C (en) * | 2014-12-01 | 2023-08-22 | Amgen Inc. | Process for manipulating the level of glycan content of a glycoprotein |
| CN122075735A (zh) | 2015-09-17 | 2026-05-26 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| EP3765521A4 (en) | 2018-03-13 | 2022-03-23 | Phanes Therapeutics, Inc. | ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF |
| KR102275930B1 (ko) * | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Folr1에 특이적으로 결합하는 항체 및 그의 용도 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101374546A (zh) * | 2005-12-16 | 2009-02-25 | Ibc医药公司 | 基于多价免疫球蛋白的生物活性装配体 |
| CN101374545A (zh) * | 2005-04-15 | 2009-02-25 | 免疫基因公司 | 消除肿瘤中的异质或混合细胞群体 |
| US20090274697A1 (en) * | 2004-02-12 | 2009-11-05 | Luigi Grasso | Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050054048A1 (en) * | 2003-07-29 | 2005-03-10 | Luigi Grasso | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| BRPI0514068B8 (pt) * | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| EP2172487A1 (en) * | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| WO2011116387A1 (en) * | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
-
2011
- 2011-10-19 KR KR1020137012669A patent/KR20140032944A/ko not_active Withdrawn
- 2011-10-19 US US13/277,161 patent/US20120164137A1/en not_active Abandoned
- 2011-10-19 CA CA2815080A patent/CA2815080A1/en not_active Abandoned
- 2011-10-19 EP EP11835098.2A patent/EP2629798A4/en not_active Withdrawn
- 2011-10-19 RU RU2013122843/10A patent/RU2013122843A/ru not_active Application Discontinuation
- 2011-10-19 AU AU2011317088A patent/AU2011317088B2/en not_active Ceased
- 2011-10-19 BR BR112013009275A patent/BR112013009275A2/pt not_active Application Discontinuation
- 2011-10-19 JP JP2013535058A patent/JP2014505012A/ja active Pending
- 2011-10-19 MX MX2013004202A patent/MX2013004202A/es unknown
- 2011-10-19 CN CN2011800503838A patent/CN103347537A/zh active Pending
- 2011-10-19 WO PCT/US2011/056966 patent/WO2012054654A2/en not_active Ceased
-
2013
- 2013-04-04 IL IL225579A patent/IL225579A0/en unknown
-
2016
- 2016-04-04 AU AU2016202082A patent/AU2016202082A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090274697A1 (en) * | 2004-02-12 | 2009-11-05 | Luigi Grasso | Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen |
| CN101374545A (zh) * | 2005-04-15 | 2009-02-25 | 免疫基因公司 | 消除肿瘤中的异质或混合细胞群体 |
| CN101374546A (zh) * | 2005-12-16 | 2009-02-25 | Ibc医药公司 | 基于多价免疫球蛋白的生物活性装配体 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118344485A (zh) * | 2024-06-18 | 2024-07-16 | 南京欧凯生物科技有限公司 | 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用 |
| CN118344485B (zh) * | 2024-06-18 | 2024-10-15 | 南京欧凯生物科技有限公司 | 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012054654A3 (en) | 2012-08-02 |
| AU2011317088A1 (en) | 2013-05-02 |
| MX2013004202A (es) | 2013-10-17 |
| US20120164137A1 (en) | 2012-06-28 |
| EP2629798A2 (en) | 2013-08-28 |
| AU2011317088B2 (en) | 2016-01-21 |
| RU2013122843A (ru) | 2014-11-27 |
| CA2815080A1 (en) | 2012-04-26 |
| AU2016202082A1 (en) | 2016-04-28 |
| JP2014505012A (ja) | 2014-02-27 |
| BR112013009275A2 (pt) | 2017-06-20 |
| WO2012054654A2 (en) | 2012-04-26 |
| EP2629798A4 (en) | 2014-05-28 |
| KR20140032944A (ko) | 2014-03-17 |
| IL225579A0 (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120164137A1 (en) | Anti-folate receptor alpha antibody glycoforms | |
| ES2691794T3 (es) | Anticuerpo anti-FOLR1 | |
| CA2991880A1 (en) | Human cd3 binding antibody | |
| JP7469305B2 (ja) | 抗pd-1抗体およびその使用 | |
| JP2019526595A (ja) | 血液癌を治療するための抗cd20抗体、pi3キナーゼ−デルタ阻害剤および抗pd−1抗体または抗pd−l1抗体の組み合わせ | |
| KR20230110523A (ko) | 델타-유사 리간드 3(dll3) 항원 결합 영역을 포함하는 단백질 및 그의 용도 | |
| KR20200124701A (ko) | 항―pd-1 항체 및 그의 용도 | |
| TW202309088A (zh) | 新的穩定抗vista抗體 | |
| CN114793422A (zh) | 抗ctla-4单克隆抗体及其制备方法与应用 | |
| CN114901364A (zh) | 用于治疗实体癌和血液癌的组合疗法 | |
| EP4671277A1 (en) | Pharmaceutical Composition of the FAP/CD40 Binding Molecule and its Pharmaceutical Use | |
| US20250270323A1 (en) | Hhla2 binding agents with novel activity | |
| CA3246716A1 (en) | ANTI-HER2/TROP2 ANTIBODIES AND THEIR USES | |
| DK2726508T3 (en) | ANTIBODIES AGAINST ADP-RIBOSYL-CYCLASE-2 | |
| US20260028405A1 (en) | Anti-cd16a antibodies and methods of use thereof | |
| WO2023138677A1 (en) | Novel anti-lag3 antibodies and derivative products | |
| EP4624492A1 (en) | Anti-ccr8 antibody and use thereof | |
| WO2024163530A2 (en) | Novel anti-ccr4 antibodies and derivative products | |
| CN117279954A (zh) | 抗人cxcr5抗体及其用途 | |
| WO2022012559A1 (zh) | 抗cldn-18.2抗体及其用途 | |
| WO2023072294A1 (en) | Novel anti-lag3 antibodies | |
| WO2023143478A1 (en) | Novel anti-cd4 and anti-pd-l1 bispecific antibodies | |
| WO2025119322A1 (en) | Gpc3 antibody-drug conjugates and use thereof | |
| TW202523694A (zh) | 抗muc16抗體及其用途 | |
| TW202542201A (zh) | 抗psma軛合物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131009 |